[{"address1": "321 Summer Street", "address2": "Suite 400", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857 330 4340", "website": "https://www.inozyme.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for rare diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of OPLL (Ossification of the Posterior Longitudinal Ligament); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 67, "companyOfficers": [{"maxAge": 1, "name": "Dr. Douglas A. Treco Ph.D.", "age": 66, "title": "CEO & Chairman", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 591875, "exercisedValue": 0, "unexercisedValue": 116098}, {"maxAge": 1, "name": "Mr. Axel  Bolte M.B.A., M.Sc.", "age": 52, "title": "Co-Founder, Senior Advisor & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 1158083, "exercisedValue": 0, "unexercisedValue": 1257688}, {"maxAge": 1, "name": "Mr. Sanjay S. Subramanian M.B.A., M.S.", "age": 47, "title": "Senior VP, CFO, Principal Accounting Officer & Corporate Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 626233, "exercisedValue": 0, "unexercisedValue": 47925}, {"maxAge": 1, "name": "Dr. Matthew  Winton Ph.D.", "age": 46, "title": "Senior VP & COO", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 526431, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Demetrios  Braddock M.D., Ph.D.", "title": "Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Soojin  Kim Ph.D.", "title": "Senior VP & Chief Technical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yves  Sabbagh Ph.D.", "title": "Senior VP, Chief Scientific Officer & Chair of the Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stefan  Riley", "title": "Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gayle  Gironda", "title": "Senior VP & Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Di Palma M.B.A.", "age": 65, "title": "Consultant", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.9947, "open": 1.0, "dayLow": 0.9202, "dayHigh": 1.03, "regularMarketPreviousClose": 0.9947, "regularMarketOpen": 1.0, "regularMarketDayLow": 0.9202, "regularMarketDayHigh": 1.03, "payoutRatio": 0.0, "beta": 1.314, "forwardPE": -0.5680247, "volume": 562870, "regularMarketVolume": 562870, "averageVolume": 702744, "averageVolume10days": 483810, "averageDailyVolume10Day": 483810, "bid": 0.6989, "ask": 1.2, "bidSize": 1, "askSize": 1, "marketCap": 59113832, "fiftyTwoWeekLow": 0.91, "fiftyTwoWeekHigh": 7.795, "fiftyDayAverage": 1.22436, "twoHundredDayAverage": 3.58639, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -7100170, "profitMargins": 0.0, "floatShares": 35862091, "sharesOutstanding": 64240200, "sharesShort": 3989178, "sharesShortPriorMonth": 4301097, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0621, "heldPercentInsiders": 0.01195, "heldPercentInstitutions": 0.92627, "shortRatio": 6.93, "shortPercentOfFloat": 0.0671, "impliedSharesOutstanding": 64240200, "bookValue": 0.9, "priceToBook": 1.0224445, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -102024000, "trailingEps": -1.62, "forwardEps": -1.62, "enterpriseToEbitda": 0.069, "52WeekChange": -0.87414503, "SandP52WeekChange": 0.06429911, "quoteType": "EQUITY", "currentPrice": 0.9202, "targetHighPrice": 23.0, "targetLowPrice": 7.0, "targetMeanPrice": 13.5, "targetMedianPrice": 13.5, "recommendationMean": 1.44444, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 113087000, "totalCashPerShare": 1.76, "ebitda": -103288000, "totalDebt": 46873000, "quickRatio": 3.35, "currentRatio": 3.56, "debtToEquity": 81.059, "returnOnAssets": -0.40131, "returnOnEquity": -1.02896, "freeCashflow": -55088500, "operatingCashflow": -91907000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "INZY", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -7.4896975, "regularMarketPrice": 0.9202, "longName": "Inozyme Pharma, Inc.", "corporateActions": [], "postMarketTime": 1743200690, "regularMarketTime": 1743192001, "exchange": "NMS", "messageBoardId": "finmb_568596329", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "postMarketChangePercent": 4.99891, "postMarketPrice": 0.9662, "postMarketChange": 0.046, "regularMarketChange": -0.074500024, "regularMarketDayRange": "0.9202 - 1.03", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 702744, "fiftyTwoWeekLowChange": 0.010199964, "fiftyTwoWeekLowChangePercent": 0.011208751, "fiftyTwoWeekRange": "0.91 - 7.795", "fiftyTwoWeekHighChange": -6.8748, "fiftyTwoWeekHighChangePercent": -0.88194996, "fiftyTwoWeekChangePercent": -87.414505, "earningsTimestamp": 1741609800, "earningsTimestampStart": 1746448200, "earningsTimestampEnd": 1746793800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.62, "epsForward": -1.62, "epsCurrentYear": -1.105, "priceEpsCurrentYear": -0.83276016, "fiftyDayAverageChange": -0.30416, "fiftyDayAverageChangePercent": -0.24842367, "twoHundredDayAverageChange": -2.6661901, "twoHundredDayAverageChangePercent": -0.74341893, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-07-24", "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "shortName": "Inozyme Pharma, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1595597400000, "displayName": "Inozyme Pharma", "trailingPegRatio": null, "__fetch_time": "2025-03-29"}]